Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.43 -0.2%	$6.63	$4.34 ▼ $12.38	$399.43M	0.46	215,853 shs	113,375 shs
CRVS Corvus Pharmaceuticals	$5.41 -1.6%	$4.45	$2.54 ▼ $10.00	$403.12M	0.42	795,710 shs	700,210 shs
KMDA Kamada	$7.02 -1.5%	$7.48	$5.17 ▼ $9.15	$403.72M	0.93	129,220 shs	43,220 shs
SAVA Cassava Sciences	$2.38 +3.0%	$2.16	$1.15 ▼ $33.98	$114.98M	-2.05	1.39 million shs	526,429 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-0.92%	+1.10%	-7.87%	+5.75%	-15.60%
CRVS Corvus Pharmaceuticals	-0.72%	+5.97%	+18.28%	+44.74%	+35.14%
KMDA Kamada	+1.13%	+2.30%	-7.16%	+3.78%	+25.97%
SAVA Cassava Sciences	+2.67%	+7.94%	-2.94%	+13.24%	-91.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.7278 of 5 stars	3.6	0.0	0.0	2.4	2.5	0.0
CRVS Corvus Pharmaceuticals	3.2289 of 5 stars	3.5	2.0	0.0	3.7	3.3	0.6
KMDA Kamada	4.7534 of 5 stars	3.3	5.0	0.0	4.2	1.7	4.4
SAVA Cassava Sciences	1.7291 of 5 stars	1.0	1.0	4.7	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.11	Buy	$22.00	242.15% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	177.26% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	85.19% Upside
SAVA Cassava Sciences	2.00	Hold	$2.00	-15.97% Downside

Current Analyst Ratings Breakdown

Latest SAVA, CRVS, KMDA, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	AURA Aura Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.81 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
KMDA Kamada	$160.95M	2.51	$0.49 per share	14.34	$4.52 per share	1.55
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$1.82 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.96	N/A	N/A	N/A	N/A	-64.44%	-54.24%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
KMDA Kamada	$14.46M	$0.34	20.65	21.94	0.75	11.22%	7.41%	5.18%	11/12/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$2.55	N/A	N/A	N/A	N/A	-66.16%	-53.11%	11/13/2025 (Estimated)

Latest SAVA, CRVS, KMDA, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SAVA Cassava Sciences	N/A	-$0.18	N/A	-$0.92	N/A	N/A
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/13/2025	Q2 2025	KMDA Kamada	$0.09	$0.13	+$0.04	$0.13	$158.59 million	$44.75 million
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.39	12.39
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
KMDA Kamada	N/A	4.00	2.21
SAVA Cassava Sciences	N/A	2.43	2.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CRVS Corvus Pharmaceuticals	46.64%
KMDA Kamada	20.38%
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	6.30%
CRVS Corvus Pharmaceuticals	28.50%
KMDA Kamada	36.10%
SAVA Cassava Sciences	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	62.12 million	58.21 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
SAVA Cassava Sciences	30	48.31 million	47.15 million	Optionable

SAVA, CRVS, KMDA, and AURA Headlines

Recent News About These Companies

Cassava Technologies Unveils AI Factory for Africa, Powered by NVIDIA Supercomputers

August 25 at 11:11 AM | thezimbabwemail.comT

Cassava Sciences (NASDAQ:SAVA) Announces Quarterly Earnings Results

August 18, 2025 | marketbeat.com

Cassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business Update

August 14, 2025 | finanznachrichten.de

Cassava Sciences reports Q2 EPS (92c) vs 13c last year

August 14, 2025 | msn.com

Cassava Reports Q2 2025 Financials Results and Provides Business Update

August 14, 2025 | globenewswire.com

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

August 7, 2025 | globenewswire.com

Ginkgo Bioworks Holdings Q2 Earnings Preview

August 6, 2025 | msn.com

Cassava Sciences Announces Positive Preclinical Results

August 6, 2025 | theglobeandmail.com

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

August 4, 2025 | globenewswire.com

SAVA - Cassava Sciences Inc Sustainability - Morningstar

July 2, 2025 | morningstar.comM

Cassava Sciences presents poster at TSC 2025 on Simufilam

June 30, 2025 | msn.com

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

June 30, 2025 | globenewswire.com

SAVA Stock Price for Cassava Sciences Inc - Morningstar

June 28, 2025 | morningstar.comM

Why cassava could be a great addition to a balanced diet

June 26, 2025 | msn.com

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava partners with Zindi to give African AI developers better tools

May 15, 2025 | techzim.co.zwT

Cassava Sciences Inc.

May 15, 2025 | barrons.com

5 ON YOUR SIDE: Lead levels in cassava flour

May 15, 2025 | kstp.comK

Cassava Technologies, Zindi collaborate on AI services

May 12, 2025 | msn.com

Cassava Technologies and Zindi collaborate to showcase African A.I. innovation

May 12, 2025 | thezimbabwemail.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAVA, CRVS, KMDA, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.43 -0.01 (-0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$6.43 0.00 (0.00%)

As of 04:11 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.41 -0.09 (-1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$5.49 +0.08 (+1.48%)

As of 04:53 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Kamada NASDAQ:KMDA

$7.02 -0.11 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$7.04 +0.02 (+0.21%)

As of 04:12 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Cassava Sciences NASDAQ:SAVA

$2.38 +0.07 (+3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 0.00 (-0.21%)

As of 05:26 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time